Supplementary Materials

Supplementary Material for:

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

Liping L. Sun,* Diego Ellerman, Mary Mathieu, Maria Hristopoulos, Xiaocheng Chen, Yijin Li, Xiaojie Yan, Robyn Clark, Arthur Reyes, Eric Stefanich, Elaine Mai, Judy Young, Clarissa Johnson, Mahrukh Huseni, Xinhua Wang, Yvonne Chen, Peiyin Wang, Hong Wang, Noel Dybdal, Yu-Waye Chu, Nicholas Chiorazzi, Justin M. Scheer, Teemu Junttila, Klara Totpal, Mark S. Dennis, Allen J. Ebens

*Corresponding author. E-mail: sun.laura{at}

Published 13 May 2015, Sci. Transl. Med. 7, 287ra70 (2015)
DOI: 10.1126/scitranslmed.aaa4802

This PDF file includes:

  • Fig. S1. Quality control analysis for anti-CD20/CD3 TDB.
  • Fig. S2. Summary of PK analysis for anti-CD20/CD3 TDB in rats.
  • Fig. S3. Representative FACS data for Fig. 1C.
  • Fig. S4. In vitro CD8+ T cell proliferation in the presence of CD20-TDB and BJAB.
  • Fig. S5. Data with three healthy human donors for statistical analysis for Fig. 1 (D to F).
  • Fig. S6. FACS gating strategy for B and T cells with blood and spleen samples of huCD20-huCD3 double-transgenic mice.
  • Fig. S7. Presence of human B and T cells in humanized NSG mice and antigen expression level for human CD20 and CD3.
  • Fig. S8. CD4+ T cell counts in humanized NSG mice upon CD20-TDB treatment.
  • Fig. S9. Control studies with rituximab and rituximab-DANA antibodies.
  • Fig. S10. FACS gating strategy for B and T cells with blood and tissue samples of cynomolgus monkeys.
  • Fig. S11. (A and B) Cytokine production in huCD20-huCD3 double-transgenic mice (A) and in cynomolgus monkeys (B) upon CD20-TDB treatment.
  • Fig. S12. Summary of sample sizes for all presented studies.

[Download PDF]